

Letter to Editor

Immunotherapy: A New Era for Breast Cancer Treatment

Zhang X*, Xi Sun, Gong W and Li X

Tongji University Cancer Institute, Tongji University School of Medicine, China

***Corresponding author:** Xiaoshen Zhang, Tongji University Cancer Institute, Tongji University School of Medicine, China**Received:** June 21, 2018; **Accepted:** July 05, 2018;**Published:** July 13, 2018

Letter to Editor

The breast cancer is one of the most fatal diseases of female. It can be categorized by various biomarkers depending on the cancer cell's own nature [1]. In the past 10 years, clinical trials had shown successful and promising efficacy in specific her2positive breast cancer patients [2]. Although breast cancer is not inherently immunogenic, recent researches have posed robust evidence of effective immunotherapy in the treatment of breast cancer. The application of immune checkpoint PD-1inhibitor pembrolizumab, has shown solid effect in every clinical setting of the breast cancer, including the metastatic breast cancer, early stage Triple-Negative breast cancer, hormone receptor positive Breast Cancer and her2 positive breast cancer patients [3-6]. Counterparts such as anti-PD-L1 antibody, atezolizumab and the CTLA-4 antibody, tremelimumab or ipilimumab posed the same positive effect [7,8]. Therefore; the immunotherapy did open a new era for breast cancer therapy, Not; Also the efficacy and safety of checkpoint inhibitor with other anticancer agents such trastuzumab/pertuzab are still needed to be warranted by multicenter clinical trials with larger amounts of participants. Furthermore, some potential biomarkers are still needed for future investigation.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

References

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med.* 2001; 344: 783-92.
2. Leyland-Jones B, Colomer R, Trudeau ME, Wardley A, Latreille J, Cameron D, et al. Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. *J Clin Oncol.* 2010; 28: 960-966.
3. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase 1b KEYNOTE-012 study. *J Clin Oncol.* 2016; 34: 2460-2467.
4. Adams S, Loi S, Toppmeyer D, Cescon DW, Laurentiis MD, Nanda R, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): preliminary data from KEYNOTE-086 cohort B. *J Clin Oncol.* 2017; 35: 1088.
5. HS Rugo, J-P Delord, S-A Im, PA Ott, SA Piha-Paul, PL Bedard, JS, et al. Abstract S5-07: preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1-positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. *Cancer Res.* 2016; 76: S5-07-S5.
6. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. *Proc Natl AcadSci U S A.* 2011; 108: 7142-7147.
7. Adams S, Diamond JR, Hamilton EP. Phase 1b trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). 2016 ASCO Annual Meeting 2016. *J Clin Oncol.* 2016; 34.
8. McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. *Clin Cancer Res: Off J Am Assoc Cancer Res.* 2016; 22: 5729-5737.